MA50068A - Formulations de copanlisib - Google Patents

Formulations de copanlisib

Info

Publication number: MA50068A
Authority: MA; Morocco
Prior art keywords: copanlisib; formulations; copanlisib formulations
Prior art date: 2017-09-08

Application number

MA050068A

Other languages

English (en)

Inventor

Julia Freundlieb

Tia Jacobs

Original Assignee

Bayer Consumer Care Ag

Bayer Pharma AG

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2017-09-08

Filing date

2018-09-06

Publication date

2021-06-02

2017-12-15 Priority claimed from EP17207771.1A external-priority patent/EP3498266A1/fr

2018-09-06 Application filed by Bayer Consumer Care Ag, Bayer Pharma AG filed Critical Bayer Consumer Care Ag

2021-06-02 Publication of MA50068A publication Critical patent/MA50068A/fr

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Oil, Petroleum & Natural Gas (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Inorganic Chemistry (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Dermatology (AREA)
Hematology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Road Signs Or Road Markings (AREA)
Luminescent Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

MA050068A 2017-09-08 2018-09-06 Formulations de copanlisib MA50068A (fr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
EP17190117		2017-09-08
EP17207771.1A EP3498266A1 (fr)	2017-12-15	2017-12-15	Formulations de copanlisib

Publications (1)

Publication Number	Publication Date
MA50068A true MA50068A (fr)	2021-06-02

Family

ID=63407234

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA050068A MA50068A (fr)	2017-09-08	2018-09-06	Formulations de copanlisib

Country Status (35)

Country	Link
US (1)	US20200281932A1 (fr)
EP (1)	EP3678644B1 (fr)
JP (2)	JP2020533292A (fr)
KR (1)	KR20200052326A (fr)
CN (1)	CN111278430A (fr)
AU (1)	AU2018328812A1 (fr)
BR (1)	BR112020004545A2 (fr)
CA (1)	CA3074890A1 (fr)
CL (1)	CL2020000584A1 (fr)
CO (1)	CO2020002628A2 (fr)
CR (1)	CR20200111A (fr)
CU (1)	CU24607B1 (fr)
DK (1)	DK3678644T3 (fr)
DO (1)	DOP2020000054A (fr)
ES (1)	ES2950663T3 (fr)
FI (1)	FI3678644T3 (fr)
GE (1)	GEP20237486B (fr)
HR (1)	HRP20230612T1 (fr)
HU (1)	HUE063178T2 (fr)
IL (1)	IL272857B2 (fr)
JO (1)	JOP20200053A1 (fr)
LT (1)	LT3678644T (fr)
MA (1)	MA50068A (fr)
MX (1)	MX2020002633A (fr)
NI (1)	NI202000019A (fr)
PH (1)	PH12020500448A1 (fr)
PL (1)	PL3678644T3 (fr)
RS (1)	RS64316B1 (fr)
SG (1)	SG11202001696QA (fr)
SI (1)	SI3678644T1 (fr)
TW (1)	TWI794288B (fr)
UA (1)	UA126817C2 (fr)
UY (1)	UY37868A (fr)
WO (1)	WO2019048527A1 (fr)
ZA (1)	ZA202002378B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP3946547A4 (fr)	2019-03-26	2023-01-18	Pocket Naloxone Corp.	Dispositifs et procédés d'administration de compositions pharmaceutiques
US11278709B1 (en)	2021-03-12	2022-03-22	Pocket Naloxone Corp.	Drug delivery device and methods for using same
EP4070785B1 (fr)	2021-04-06	2023-11-08	Synthon B.V.	Composition lyophilisée d'un sel de copanlisib
CN115252613B (zh) *	2022-08-09	2024-01-12	北京清华长庚医院	药物组合物及其在逆转仑伐替尼耐药性中的用途
US20240100019A1 (en) *	2022-09-28	2024-03-28	Urogen Pharma Ltd.	Compositions comprising a thermoreversible hydrogel, and having an extended in-use period

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004029055A1 (fr)	2002-09-30	2004-04-08	Bayer Pharmaceuticals Corporation	Derives d'azole-pyrimidines fondues
AR064106A1 (es)	2006-12-05	2009-03-11	Bayer Schering Pharma Ag	Derivados de 2,3-dihidroimidazo [1,2-c] quinazolina sustituida utiles para el tratamiento de enfermedades y trastornos hiper-proliferativos asociados con la angiogenesis
EP2508525A1 (fr)	2011-04-05	2012-10-10	Bayer Pharma Aktiengesellschaft	Sels de 2,3-dihydroimidazo[1,2-C]quinazoline substitutés
EP3018127A1 (fr)	2014-11-07	2016-05-11	Bayer Pharma Aktiengesellschaft	Synthèse de copanlisib et son sel de dichlorhydrate
SG11201806274SA (en) *	2016-02-01	2018-08-30	Bayer Pharma AG	Copanlisib biomarkers
TN2018000272A1 (en) *	2016-02-01	2020-01-16	Bayer Pharma AG	Copanlisib biomarkers

2018
- 2018-09-06 HU HUE18762107A patent/HUE063178T2/hu unknown
- 2018-09-06 JO JOP/2020/0053A patent/JOP20200053A1/ar unknown
- 2018-09-06 EP EP18762107.3A patent/EP3678644B1/fr active Active
- 2018-09-06 RS RS20230535A patent/RS64316B1/sr unknown
- 2018-09-06 ES ES18762107T patent/ES2950663T3/es active Active
- 2018-09-06 CR CR20200111A patent/CR20200111A/es unknown
- 2018-09-06 TW TW107131361A patent/TWI794288B/zh not_active IP Right Cessation
- 2018-09-06 MA MA050068A patent/MA50068A/fr unknown
- 2018-09-06 HR HRP20230612TT patent/HRP20230612T1/hr unknown
- 2018-09-06 WO PCT/EP2018/073965 patent/WO2019048527A1/fr active Application Filing
- 2018-09-06 JP JP2020513544A patent/JP2020533292A/ja active Pending
- 2018-09-06 MX MX2020002633A patent/MX2020002633A/es unknown
- 2018-09-06 PL PL18762107.3T patent/PL3678644T3/pl unknown
- 2018-09-06 KR KR1020207009732A patent/KR20200052326A/ko active Search and Examination
- 2018-09-06 DK DK18762107.3T patent/DK3678644T3/da active
- 2018-09-06 AU AU2018328812A patent/AU2018328812A1/en active Pending
- 2018-09-06 FI FIEP18762107.3T patent/FI3678644T3/fi active
- 2018-09-06 IL IL272857A patent/IL272857B2/en unknown
- 2018-09-06 SG SG11202001696QA patent/SG11202001696QA/en unknown
- 2018-09-06 UA UAA202002130A patent/UA126817C2/uk unknown
- 2018-09-06 US US16/644,472 patent/US20200281932A1/en not_active Abandoned
- 2018-09-06 CU CU2020000017A patent/CU24607B1/es unknown
- 2018-09-06 SI SI201830943T patent/SI3678644T1/sl unknown
- 2018-09-06 GE GEAP201815306A patent/GEP20237486B/en unknown
- 2018-09-06 CA CA3074890A patent/CA3074890A1/fr active Pending
- 2018-09-06 LT LTEPPCT/EP2018/073965T patent/LT3678644T/lt unknown
- 2018-09-06 CN CN201880072307.9A patent/CN111278430A/zh active Pending
- 2018-09-06 BR BR112020004545-4A patent/BR112020004545A2/pt not_active Application Discontinuation
- 2018-09-07 UY UY0001037868A patent/UY37868A/es not_active Application Discontinuation
2020
- 2020-03-05 PH PH12020500448A patent/PH12020500448A1/en unknown
- 2020-03-06 DO DO2020000054A patent/DOP2020000054A/es unknown
- 2020-03-06 CL CL2020000584A patent/CL2020000584A1/es unknown
- 2020-03-06 NI NI202000019A patent/NI202000019A/es unknown
- 2020-03-09 CO CONC2020/0002628A patent/CO2020002628A2/es unknown
- 2020-05-04 ZA ZA2020/02378A patent/ZA202002378B/en unknown
2023
- 2023-03-07 JP JP2023034647A patent/JP2023071917A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
JP2023071917A (ja)	2023-05-23
NI202000019A (es)	2020-08-28
FI3678644T3 (fi)	2023-07-28
CL2020000584A1 (es)	2020-08-21
TW201919636A (zh)	2019-06-01
PL3678644T3 (pl)	2023-09-11
US20200281932A1 (en)	2020-09-10
CA3074890A1 (fr)	2019-03-14
EP3678644A1 (fr)	2020-07-15
EP3678644B1 (fr)	2023-05-03
IL272857A (en)	2020-04-30
SI3678644T1 (sl)	2023-08-31
UY37868A (es)	2019-04-30
IL272857B2 (en)	2024-03-01
PH12020500448A1 (en)	2021-02-08
WO2019048527A1 (fr)	2019-03-14
CU20200017A7 (es)	2020-11-30
BR112020004545A2 (pt)	2020-09-08
KR20200052326A (ko)	2020-05-14
JOP20200053A1 (ar)	2020-03-08
LT3678644T (lt)	2023-06-26
ES2950663T3 (es)	2023-10-11
CU24607B1 (es)	2022-06-06
DOP2020000054A (es)	2020-09-30
HUE063178T2 (hu)	2023-12-28
UA126817C2 (uk)	2023-02-08
ZA202002378B (en)	2023-10-25
GEP20237486B (en)	2023-03-27
MX2020002633A (es)	2020-07-13
HRP20230612T1 (hr)	2023-09-29
CO2020002628A2 (es)	2020-04-01
AU2018328812A1 (en)	2020-03-12
DK3678644T3 (da)	2023-07-31
JP2020533292A (ja)	2020-11-19
CR20200111A (es)	2020-07-24
RS64316B1 (sr)	2023-08-31
SG11202001696QA (en)	2020-03-30
TWI794288B (zh)	2023-03-01
CN111278430A (zh)	2020-06-12
IL272857B1 (en)	2023-11-01

Publication	Publication Date	Title
DK3688162T3 (da)	2024-05-13	Formuleringer
DK3731771T3 (da)	2023-08-28	V462033dk00
MA50657A (fr)	2020-08-05	Formulations de niraparib
DE202018003363U8 (de)	2019-01-24	Handgelenkssphygmomanometer
CL2018000524S1 (es)	2018-10-05	Golilla
EP3588580A4 (fr)	2020-12-02	Diode schottky mos à tranchée
EP3634404C0 (fr)	2024-11-20	Inhibiteurs de magl à base de pyrazole
DK3351526T3 (da)	2021-02-08	Diisopentylterephthalat
EP3589248A4 (fr)	2021-01-06	Cryothérapies
EP3697802A4 (fr)	2021-11-24	Analogues de saponine triterpénique
DK3571580T3 (da)	2021-10-18	Load-logical-and-shift-guarded-instruktion
EP3618836A4 (fr)	2021-01-13	Analogues de saponine triterpénique
EP3580321A4 (fr)	2020-12-02	Compositions de nettoyage
PL3703518T3 (pl)	2024-11-12	Formulacja ulegająca aerozolowaniu
DK3568655T3 (da)	2023-04-17	Rekuperator
DK3651736T3 (da)	2021-09-27	Langtidsvirkende formuleringer
EP3364945C0 (fr)	2024-12-04	Formulation solide
EP3634397A4 (fr)	2021-03-17	Chromophores ir à base de polyméthine hétérocyclyle
DK3612237T3 (da)	2021-12-06	Genterapi
EP3575467A4 (fr)	2020-03-18	Tissu non tissé filé-lié
MA50068A (fr)	2021-06-02	Formulations de copanlisib
EP3654852A4 (fr)	2020-06-17	Garrot
EP3714787A4 (fr)	2021-03-17	Biocapteur
DK3568506T3 (da)	2021-03-01	Offeranode
EP3569893A4 (fr)	2020-01-08	Tendeur de chaîne